PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.31%
Revenue growth of 3.31% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
2.91%
Gross profit growth of 2.91% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
7.71%
Positive EBIT growth while Healthcare median is negative. Peter Lynch might see a strong competitive advantage in operations.
7.71%
Positive operating income growth while Healthcare is negative. Peter Lynch would spot a big relative advantage here.
4.16%
Positive net income growth while Healthcare median is negative. Peter Lynch would view this as a notable competitive advantage.
4.15%
EPS growth of 4.15% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
4.15%
Diluted EPS growth of 4.15% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Healthcare median is 0.19%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Healthcare median is 0.17%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.83%
10Y CAGR of 35.83% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
51.99%
5Y CAGR of 51.99% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
23.42%
3Y CAGR of 23.42% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.42%
Net income/share CAGR of 53.42% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
33.73%
5Y net income/share CAGR > 1.5x Healthcare median of 1.61%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
23.99%
3Y net income/share CAGR of 23.99% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
167.66%
Equity/share CAGR of 167.66% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
110.15%
5Y equity/share CAGR of 110.15% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
52.73%
3Y equity/share CAGR of 52.73% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
77.78%
3Y dividend/share CAGR of 77.78% while Healthcare is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
14.05%
AR growth of 14.05% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-0.11%
Decreasing inventory while Healthcare is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-0.78%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
2.01%
Positive BV/share change while Healthcare median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-7.70%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
1.88%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.